Business Wire

CO-OPTIV-SECURITY

3.6.2019 20:07:03 CEST | Business Wire | Press release

Share
Optiv Security Doubles Down On Client Success with New Services Approach, Business and Engagement Model; Further Advances Ability to Help Global Clients Optimize, Integrate and Operationalize Cybersecurity

While industries are being completely reinvented at an ever-accelerating pace, the overall approach to cybersecurity has not similarly evolved to address the new security challenges presented by rapid digital transformation. Talent shortages, expanding attack surfaces, and constant breaches are all symptoms of an unnecessarily complex and inefficiently constructed cybersecurity world. Optiv Security , a global cybersecurity integrator delivering end-to-end cybersecurity solutions, today announced it has implemented a new cybersecurity services approach, business and engagement model that transforms the way cybersecurity is consumed and applied. Optiv’s innovative approach is specifically designed to deliver to organizations integrated cybersecurity solutions that address the speed of business change, by providing new consumption and outcome-based consulting services and cybersecurity solutions that ultimately achieve higher performance and reduced overall operational costs.

Specifically, the company is launching the following to more tightly align its breadth of capabilities and client-centric approach, to bring to market more focused global cybersecurity solutions that encompass people, process and technology.

  • Newly launched Global Services and Operations Organization – Optiv has redesigned its services approach centered on client-focused outcomes and is delivering global capabilities to assist clients along their cybersecurity journeys. The company’s breadth of services addresses the full lifecycle of client security needs – with newly launched business lines for Advisory, Integration & Innovation, and CyberOperations - providing global clients with the required focus and scale to execute on full end-to-end cyber risk, cyber digital and cybersecurity projects and programs.
  • Cyber-as-a-Service (CaaS TM ) Platform – designed to ensure organizations benefit from fully-integrated solutions that scale on-demand with business needs and automatically adapt to shifting business requirements. This approach enables Optiv to deliver complex and integrated solutions with an innovative integrated technology stack focused on client outcomes. Optiv’s new CaaSTM offerings can be consumed alone, or combined with Optiv’s advisory, integration or managed services to harden security fundamentals across four critical areas of modern business risk:
    • Risk management and compliance, including resilience and assurance;
    • Cyber digital transformation, including cloud, orchestration, automation and big data;
    • Threat management, including protection, detection and response; and
    • Identity and data management.
  • Global Services Demand (GSD) Organization – Coordinating Partner and Teaming Delivery Model – Optiv created GSD to provide clients with the optimal mix of centralized oversight and buying power, and localized technical resources and expertise. This new engagement model also brings together a seasoned team of regionally-focused senior technical services executives to give clients an important engagement layer atop Optiv’s more than 1,300 deeply skilled and specialized cybersecurity delivery practitioners. These executives serve as global coordinating partners for our clients, acting as a single point of accountability to drive excellence for complex end-to-end cybersecurity services and solutions.

“After more than 40 years since the first virus was launched, the approach to addressing cybersecurity issues has followed the same action and response formula. The challenge is that the world has changed, while the approach to cybersecurity has not kept pace,” said Chad Holmes, chief services and operations officer. “Industries are being completely reinvented – through digital transformation, cloud and data models, Artificial Intelligence (AI), globalization and much more – while cybersecurity gaps expand as symptoms of a historical approach to a new and different business model.”

Holmes continued, “Our new Cyber-as-a-Service consumption model, which we are launching based on client feedback and to meet growing market demand, strongly complements our traditional services model. It enables clients to have a choice in their cybersecurity consumption model, and thereby transform their organizational cybersecurity approach, while benefiting from the same cloud economics that have been used to transform entire industries. This custom developed, innovative and integrated approach provides organizations with increased flexibility and choice in how they procure cybersecurity – from standalone tools to integrated solutions – addressing complex security problems and delivering better alignment to unique business requirements. Optiv is extremely excited to bring to market our new Cyber-as-a-Service, integrated business services and client engagement models, that will increase our ability to provide clients with the right global resources at the right time so that we can truly serve their best interests.”

Please visit our website for more information about our cybersecurity solutions and capabilities.

Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn: www.linkedin.com/company/optiv-inc
Facebook: www.facebook.com/optivinc
YouTube: https://www.youtube.com/c/OptivInc
Blog: www.optiv.com/resources/blog

About Optiv Security

Optiv is a global cybersecurity solutions integrator – a “one-stop” trusted partner with a singular focus on cybersecurity. Our end-to-end cybersecurity capabilities span risk management and transformation, cyber digital transformation, threat management, cyber operations, identity and data management, and integration and innovation, helping organizations realize stronger, simpler and more cost-efficient cybersecurity programs that support business requirements and outcomes. At Optiv, we are modernizing cybersecurity to enable clients to innovate their consumption models, integrate infrastructure and technology to maximize value, achieve measurable outcomes, and realize complete solutions and business alignment. For more information about Optiv, please visit us at www.optiv.com .

Contact:

Jason Cook (816) 701-3374 Jason.cook@optiv.com or Brett Ater (913) 304-7683 Brett.ater@optiv.com

Link:

ClickThru

Social Media:

https://www.facebook.com/OptivInc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye